New Technologies Help Clinicians Identify Head Trauma and Stroke

The Artificial Intelligence (A.I.)-based clinical decision support application is intended to help imaging experts in acute care settings, such as hospital emergency rooms, detect bleeding in the brain.

The agreement was signed between MedyMatch, and the IBM Watson Health collaborative. In the next phase the companies plan to develop interoperability capabilities between the MedyMatch application and IBM Watson Health Imaging products. MedyMatch Technology solutions make use of advanced cognitive analytics, and A.I. to provide real-time decision support tools for acute care settings.

The MedyMatch intracranial bleed assessment application is currently undergoing a clinical trial, with the aim to achieve US Food and Drug Administration (FDA) Class III Premarket Approval (PMA).

Chairman and CEO of MedyMatch, Gene Saragnese, said, "The opportunity to license our deep vision application to IBM Watson Health creates a unique value proposition in healthcare. Engaging closely with IBM allows for a near-zero footprint implementation at a customer location delivering 'A.I. to the bedside' where I believe the future of healthcare lies. At MedyMatch, we believe improvements in the interpretation of data will lead to better decisions, better decisions will lead to better outcomes for patients and lower cost for healthcare. This is what drives us forward every day."